Fidelity FHLC vs. State Street XLV: Which Health Care ETF Delivers?
1h ago|4 min readStandard
Fazen Markets Editorial Desk
Collective editorial team · methodology
healthcare-etffhcl
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
The choice between two dominant health care exchange-traded funds (ETFs) involves a detailed examination of structure and sector exposure. Data released in May 2026 shows the Fidelity MSCI Health Care ETF FHLC and the Health Care Select Sector SPDR Fund XLV, while tracking the same broad industry, have delivered divergent returns. The performance difference underscores a strategic decision for investors between a market-cap-weighted index and a modified equal-weighted approach. This analysis compares the core metrics, holdings, and flow trends defining the $90 billion health care ETF market.
Health care sector investing regained prominence in 2026 as a defensive play amid persistent macroeconomic uncertainty. The Federal Reserve's policy path remained data-dependent, with the 10-year Treasury yield holding above 4.5% through the first quarter. This elevated rate environment pressured growth stocks but benefited sectors with stable earnings and pricing power, like pharmaceuticals and managed care.
The catalyst for renewed scrutiny of health care ETF construction is a widening performance gap. Over multi-year periods, the two largest passive vehicles have exhibited periods of significant divergence, driven by their different indexing methodologies. The last major divergence occurred in 2022 during the post-pandemic biotech sell-off, where XLV's heavy pharmaceutical tilt provided over 300 basis points of outperformance versus FHLC's broader exposure.
Investor preference has shifted towards granularity in sector allocation, moving beyond simple sector bets to fund-specific construction. The health care sector's internal dynamics—spanning high-growth biotech, stable pharmaceuticals, regulated insurers, and volatile device makers—make ETF selection critical.
As of late May 2026, XLV managed approximately $38.2 billion in assets, dwarfing FHLC's $2.1 billion. Despite the size disparity, both funds are highly liquid, with XLV averaging a daily volume of 5.2 million shares. The key differentiator is the index. XLV tracks the Health Care Select Sector Index, which includes only S&P 500 health care constituents, weighted by market capitalization. FHLC tracks the MSCI USA IMI Health Care Index, which includes large, mid, and small-cap stocks with a modified equal-weight tilt.
This structural difference creates distinct portfolio concentrations. XLV's top three holdings—UnitedHealth Group UNH, Eli Lilly LLY, and Johnson & Johnson JNJ—comprise over 35% of the fund. In contrast, FHLC's top three holdings represent just under 20% of assets. The sector allocation also varies meaningfully within health care.
| Metric | XLV | FHLC |
|---|---|---|
| Pharma + Biotech Weight | ~47% | ~40% |
| Health Care Equipment | ~15% | ~19% |
| Managed Care | ~22% | ~17% |
| YTD Return (24 May '26) | +6.8% | +5.1% |
XLV's heavier allocation to mega-cap pharmaceutical stocks, which have outperformed in 2026 on drug pipeline successes, explains its 170-basis-point year-to-date advantage. The fund's expense ratio is 0.09%, undercutting FHLC's 0.084% by a negligible 0.6 basis points.
XLV's outperformance signals a market reward for concentration in the largest, most profitable health care names. This benefits tickers like Eli Lilly LLY and Novo Nordisk NVO, which dominate the obesity drug market and command significant index weight. Managed care giants UnitedHealth UNH and Elevance Health ELV also contribute positively due to their stable earnings profiles.
Conversely, FHLC's more diversified approach provides greater exposure to mid-cap biotechnology and life sciences tools companies. This has been a relative drag in 2026 as higher financing costs pressure smaller firms. Tickers like Illumina ILMN and Vertex Pharmaceuticals VRTX hold more sway in FHLC but have lagged the mega-caps.
A key risk for XLV investors is over-concentration. A setback for one of its top three holdings could disproportionately impact the fund, a vulnerability less pronounced in FHLC. However, the counter-argument is that mega-cap dominance is a persistent feature of the current market cycle, favoring concentrated bets.
Institutional flow data shows consistent net inflows into XLV, reinforcing its status as the sector's liquidity benchmark. Active managers and hedge funds often use XLV for tactical sector exposure, while FHLC attracts investors seeking a purer, broader replication of the health care universe without S&P 500 membership constraints.
The immediate catalyst for relative performance is the Q2 2026 earnings season, commencing in mid-July. Results from pharmaceutical leaders will directly test XLV's heavy reliance on that sub-sector. Any guidance cuts from major players could swiftly reverse its year-to-date advantage.
A secondary watchpoint is the Federal Open Market Committee meeting on 17 June. A more dovish-than-expected stance could trigger a rally in rate-sensitive biotech stocks, which would benefit FHLC's broader portfolio. Key technical levels to monitor are XLV's 50-day moving average, currently near $142.50, which has acted as support.
The long-term outlook hinges on drug pricing legislation and Medicare negotiation outcomes, expected to see renewed legislative proposals in Q3 2026. Stricter measures would disproportionately impact the large pharmaceutical holdings within XLV, while the diversified exposure of FHLC might offer better insulation.
FHLC tracks the MSCI USA IMI Health Care Index, which includes large, mid, and small-cap U.S. health care stocks with a modified equal-weight approach, leading to lower concentration in the top holdings. XLV tracks only the health care companies within the S&P 500, weighted strictly by market capitalization, resulting in a portfolio heavily tilted towards the sector's largest giants like UnitedHealth and Eli Lilly.
The expense ratios are nearly identical, making cost a non-factor in the decision. XLV charges 0.09% annually, while FHLC charges 0.084%. This difference of 0.6 basis points translates to a cost of just $0.60 per year on a $10,000 investment, an immaterial amount compared to the performance divergence driven by their different portfolio constructions.
Both ETFs distribute dividends quarterly. XLV's dividend yield has historically been slightly higher, often by 10-30 basis points, due to its heavier weighting in mature, cash-generating pharmaceutical and managed care companies. FHLC's yield is marginally lower as it includes more growth-oriented biotech and device companies that typically reinvest cash flow rather than distribute it.
ETF selection in health care hinges on an investor's conviction in continued mega-cap dominance versus broader industry exposure.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.